Mercedes Álvarez

Mercedes Álvarez

Auto-generated profile, based on publicly available information

Mercedes Álvarez

Institute for Research in Biomedicine Barcelona Science Park-University of Barcelona Baldiri i Reixac 10 08028 Barcelona Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Chemical Reviews
Verified
Journal Article
Closed access
AGAlejandro Gil
Alejandro Gil
Fernando AlbericioFernando Albericio
Fernando Albericio
MÁMercedes Álvarez
Mercedes Álvarez

1 December 2016 in ACS Chemical Biology
Verified
Journal Article
Open access
KMKamil Makowski
Kamil Makowski
LVLuisa Vigevani
Luisa Vigevani
Fernando AlbericioFernando Albericio
Fernando Albericio
JVJuan Valcárcel
Juan Valcárcel
MÁMercedes Álvarez
Mercedes Álvarez
Important links exist between the process of pre-mRNA splicing and cancer, as illustrated by the frequent mutation of splicing factors in tumors and the emergence of various families of antitumor drugs that target components of the splicing machinery, notably SF3B1, a protein subunit of spliceosomal U2 small nuclear ribonucleoprotein particle (snRNP). Sudemycins are synthetic compounds that harbor a pharmacophore common to various classes of splicing inhibitors. Here, we describe the synthesis and functional characterization of novel sudemycin analogues that functionally probe key chemical groups within this pharmacophore. Our results confirm the importance of a conjugated diene group and in addition reveal significant spatial flexibility in this region of the molecule. Sudemycin K, a derivative that replaces the pharmacophore’s oxycarbonyl by an amide group, displays improved potency as an inhibitor of cancer cell proliferation, as a regulator of alternative splicing in cultured cells and as an inhibitor of in vitro spliceosome assembly. Sudemycin K displays higher stability, likely related to the replacement of the oxycarbonyl group, which can be a substrate of esterases, by an amide group. The activity and special reactivity of sudemycin K can pave the way to the synthesis and evaluation of a variety of novel sudemycin derivatives.

4 January 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ACAlbert Canals
Albert Canals
RARaquel Arribas-Bosacoma
Raquel Arribas-Bosacoma
Fernando AlbericioFernando Albericio
Fernando Albericio
MÁMercedes Álvarez
Mercedes Álvarez
JAJoan Aymamí
Joan Aymamí
MCMiquel Coll
Miquel Coll
Variolin B is a rare marine alkaloid that showed promising anti-cancer activity soon after its isolation. It acts as a cyclin-dependent kinase inhibitor, although the precise mechanism through which it exerts the cytotoxic effects is still unknown. The crystal structure of a variolin B bound to a DNA forming a pseudo-Holliday junction shows that this compound can also contribute, through intercalative binding, to either the formation or stabilization of multi-stranded DNA forms.

7 May 2019 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
JJJohn A. Joule
John A. Joule
MÁMercedes Álvarez
Mercedes Álvarez

1 January 2006 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ACAlvarez Cironi
Alvarez Cironi
MAMercedes Alvarez
Mercedes Alvarez
Fernando AlbericioFernando Albericio
Fernando Albericio
Solid-phase chemistry, first introduced for peptide synthesis in the 1960s, has become an integral part of organic synthetic methodology. Presented herein is an overview of recent examples of the use of solid-phase in the preparation of non-peptidic natural products and related compounds, encompassing on-resin total syntheses as well as the use of polymer-supported reagents in solution.

31 May 2014 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XJXavier Just-Baringo
Xavier Just-Baringo
Fernando AlbericioFernando Albericio
Fernando Albericio
MAMercedes Alvarez
Mercedes Alvarez
Thiazoline and thiazole heterocycles are privileged motifs found in numerous peptide-derived natural products of biological interest. During the last decades, the synthesis of optically pure building blocks has been addressed by numerous groups, which have developed a plethora of strategies to that end. Efficient and reliable methodologies that are compatible with the intricate and capricious architectures of natural products are a must to further develop their science. Structure confirmation, structure-activity relationship studies and industrial production are fields of paramount importance that require these robust methodologies in order to successfully bring natural products into the clinic. Today’s chemist toolbox is assorted with many powerful methods for chiral thiazoline and thiazole synthesis. Ranging from biomimetic approaches to stereoselective alkylations, one is likely to find a suitable method for their needs.